A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

Screening for prostate cancer using a blood test likely reduces the risk of dying from prostate cancer and may also reduce the risk of dying from any cause. Screening likely makes little to no ...

A groundbreaking blood test could enable doctors to identify failing prostate cancer treatment earlier, a trial found.

For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are ...

Prostate cancer is one of the most common cancers that occur in men. While it can be life-threatening, the disease is treatable, and the earlier it is detected, the better the treatment outcome.

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus ...

Prostate-specific antigen (PSA) is a protein made by the prostate gland. A high PSA level could be a sign of an enlarged prostate, inflammation called prostatitis, or prostate cancer. The PSA test ...